Sanofi (Japan)

Recent papers from Sanofi (Japan)

1. Development of a simplified population pharmacokinetic–pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatmentCancer Chemotherapy and Pharmacology · 2026
2. DDIapp —A Web‐Based Application for Static Drug–Drug Interaction AssessmentCPT Pharmacometrics & Systems Pharmacology · 2026
3. Characterization of Prurigo Nodules in Adults With Moderate‐To‐Severe Atopic Dermatitis in Japan: A 2‐Year Observational StudyThe Journal of Dermatology · 2026
4. Disease burden and quality of life in caregivers of infants with RSV lower respiratory tract infections in JapanJapanese Journal of Infectious Diseases · 2026
5. Awareness and Utilization of the Revised Second International Staging System ( R2 ‐ ISS ) and 1q21 Gain/Amplification Testing: A Nationwide Web‐Based Survey of Hematologists in JapanCancer Medicine · 2026
6. Identification of a Novel POLR3F Gene Variant in a Patient with Susceptibility to Varicella-Zoster Virus InfectionJournal of Human Immunity · 2026
7. Spatial and temporal variability of respiratory syncytial virus disease seasonality in Japan, 2012–2024Pediatrics International · 2025
8. Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension studyAllergology International · 2025
9. Prevalence, Comorbidities, and Current Management of Chronic Spontaneous Urticaria in Japan: Retrospective Claims Database Study.2025
10. Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal PolypsThe Laryngoscope · 2025
11. Caregiver Burden Associated With Respiratory Syncytial Virus (RSV) Infection in Young Children in JapanCureus · 2025
12. Reduction of Rescue Treatment With Dupilumab for Chronic Rhinosinusitis With Nasal Polyps in JapanThe Laryngoscope · 2025
13. Cost-effectiveness and public health impact of using high dose influenza vaccine in the Japanese older adultsJournal of Medical Economics · 2025
14. Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trialsAnnals of Hematology · 2025
15. Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in JapanJapanese Journal of Clinical Oncology · 2025
16. Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in JapanInfectious Diseases and Therapy · 2025
17. Current Status of Prurigo Nodularis in Japan: A Retrospective Study Using a Health Insurance Claims DatabaseJournal of Clinical Medicine · 2025
18. Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database StudyAdvances in Therapy · 2025
19. Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative ReviewInternational Journal of Urology · 2025
20. Efficacy and safety of avalglucosidase alfa in Japanese patients with late-onset and infantile-onset Pompe diseases: A case series from clinical trialsMolecular Genetics and Metabolism Reports · 2024